Orchard Therapeutics
Focus: Orchard Therapeutics is a Boston-based public biotech specializing in ex-vivo autologous hematopoietic stem cell gene therapy for rare genetic diseases. The company operates in the high-potential cell and gene therapy markets, currently advancing multiple Phase 1/2 and Phase 3 programs.
Profile data last refreshed 11h ago · AI intelligence enriched 3w ago
Funding Stage
PUBLIC
Open Jobs
0
About Orchard Therapeutics
AI assessmentNot HiringNo open roles listed right now. Follow Orchard Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from Orchard Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Data completeness
3/9 — Basic
Company HealthStrong
Pipeline
Mid-stage
2 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
The Myelin Disorders Biorepository Project
LeukodystrophyImaging
MucopolysaccharidosesClinical Trials (1)
Help build intelligence for Orchard Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.